Ads
related to: sarepta s- Treatment Support Options
Discover Personalized
Support Programs for ELEVIDYS
- Helpful Patient Resources
Download the Patient
Treatment Guide
- Treatment Support Options
Search results
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
Zacks via Yahoo Finance· 2 years agoSarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on...
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
Zacks via Yahoo Finance· 4 months agoSarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA,...
Sarepta data show new Duchenne drug’s potency, but highlight side effects
BioPharma Dive via Yahoo Finance· 4 months agoA successor medicine to Sarepta's Exondys 51 appeared better at boosting dystrophin protein...
Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel
Zacks via Yahoo Finance· 1 year agoThe FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene...
US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids
Reuters via Yahoo News· 12 months agoThe U.S. health regulator has granted accelerated approval to Sarepta Therapeutics'...
Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates
Zacks via Yahoo Finance· 2 years agoSarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for...
A Comprehensive Look at Sarepta's Growth and Innovation
GuruFocus.com via Yahoo Finance· 2 months agoSarepta Therapeutics, Inc. (NASDAQ:SRPT) is an American pharmaceutical company leading the global...
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Motley Fool via Yahoo Finance· 6 months agoCould the rare-disease-focused biotech Sarepta Therapeutics (NASDAQ: SRPT) one day become a...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoSarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2023 Earnings Call Transcript May 2, 2023 Operator: Good...
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
Motley Fool via Yahoo Finance· 5 months agoSarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off...
Ads
related to: sarepta s